biochem pharma one of canada's largest biotechnology companies is taking a drug it is developing with glaxo europe's biggest pharmaceutical company into the last stage of clinical trials writes daniel green trials so far have shown lamivudine to be far superior to existing treatments for hepatitis b said dr francesco bellini president of the montreal company which is hoping to launch the drug in 1997 the deal with glaxo gives the uk company marketing rights outside north america with a joint venture operating in canada and biochem selling alone in the us